Misfolded alpha‐synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment
European Journal of Neurology · 2024-04 · 31 (4)
DOI: 10.1111/ene.16206 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 25.01.2024. Verfasst von Richard Smith und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Neurologic Study, La Jolla, California, USA. Hauptthemen laut MEDLINE: alpha-Synuclein, Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Alpha‐synuclein (α‐Syn) oligomers and fibrils have been shown to augment the aggregation of TAR DNA‐binding Protein 43 (TDP‐43) monomers in vitro, supporting the idea that TDP‐43 proteinopathies such as ALS may be modulated by the presence of toxic forms of α‐Syn. Recently, parkinsonian features were reported in a study of European patients and Lewy bodies have been demonstrated pathologically in a similar series of patients. Based on these and other considerations, we sought to determine whether seed‐competent α‐Syn can be identified in spinal fluid of patients with ALS including familial, sporadic, and Guamanian forms of the disease.
Methods
Based on the finding that α‐Syn has been found to be a prion‐like protein, we have utilized a validated α‐Synuclein seed amplification assay to determine if seed‐competent α‐Syn could be detected in the spinal fluid of patients with ALS.
Results
Toxic species of α‐Syn were detected in CSF in 18 of 127 ALS patients, 5 of whom were from Guam. Two out of twenty six samples from patients with C9orf72 variant ALS had positive seed‐amplification assays (SAAs). No positive tests were noted in superoxide dismutase type 1 ALS subjects ( n = 14). The SAA was negative in 31 control subjects.
Conclusions
Our findings suggest that a sub‐group of ALS occurs in which self‐replicating α‐Syn is detectable and likely contributes to its pathogenesis. This finding may have implications for the diagnosis and treatment of this disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Neurologic Study, La Jolla, California, USA.
- Amprion Clinical Laboratory, San Diego, California, USA.
- Barrow Neurological Institute, Phoenix, Arizona, USA.
- Binghamton University, Binghamton, New York, USA.
- University of Ulm, Ulm, Germany.
- University of California, San Diego, La Jolla, California, USA.
ORCID-Profile: Richard Smith
Zitieren
APA
Smith, R., Hovren, H., Bowser, R., Bakkar, N., Garruto, R., Ludolph, A., Ravits, J., Gaertner, L., Murphy, D., & Lebovitz, R. (2024). Misfolded alpha‐synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment. European Journal of Neurology, 31(4). https://doi.org/10.1111/ene.16206
Vancouver
Smith R, Hovren H, Bowser R, Bakkar N, Garruto R, Ludolph A, et al. Misfolded alpha‐synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment. European Journal of Neurology. 2024;31(4). doi:10.1111/ene.16206
BibTeX
@article{Smith2024,
author = {Smith, Richard and Hovren, Hanna and Bowser, Robert and Bakkar, Nadine and Garruto, Ralph and Ludolph, Albert and Ravits, John and Gaertner, Lia and Murphy, Davan and Lebovitz, Russ},
title = {Misfolded alpha‐synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment},
journal = {European Journal of Neurology},
year = {2024},
volume = {31},
number = {4},
doi = {10.1111/ene.16206}
}
EUVIMED